AI More Accurately Identifies Patients With Advanced Lung Cancer Who Respond to Immunotherapy
Researchers compared AI-powered digital scoring with traditional manual scoring of the PD-L1 immune biomarker to determine if a new immunotherapy treatment, atezolizumab, could benefit patients with advanced non-small cell lung cancer.
Combination Therapies Benefit Patients With Advanced Non-Small Cell Lung Cancer
An ongoing phase II study led by a Yale Cancer Center researcher reveals that combining pembrolizumab with other treatments reduced the size of target tumors, resulting in a higher response rate for patients with advanced NSCLC.
Trial Shows Significant Disease-free Survival for Patients Diagnosed With Non-small Cell Lung Cancer
The new data show there are ongoing benefits for patients taking osimertinib, including prolonged disease-free survival (DFS) over placebo, reduced risk of local and distant metastases (spread of tumor), and improved central nervous system DFS.
Yale Cancer Center Study Characterizes Link Between Drug Resistance and Central Nervous System Relapse
A new study from Yale Cancer Center characterizes the functional link between drug resistance and central nervous system (CNS) relapse. The findings from a study led by Don Nguyen, PhD, BS, Associate Professor of Pathology and Medicine (Medical Oncology) and Assistant Yale Cancer Center Director for Research Development, were recently published in the journal Nature Communications.
Yale Pulmonologist Dr. Hilary Cain Outlines How to Improve Lung Cancer Screening Numbers in the U.S.
Lung cancer is a leading cause of death in the United States, accounting for 25 percent of cancer deaths, yet it is estimated that only 6 to 8 percent of eligible people in the U.S. are screened for the disease. Hilary Cain, MD, says we need to do better. Cain is an associate professor of medicine (pulmonary, critical care and sleep medicine) at Yale School of Medicine, and is also the section chief of pulmonary, critical care and sleep medicine at VA CT Healthcare System, West Haven.
New Class of Oncogenic Fusions Revealed in Lung and Pancreatic Cancer
A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development. The research is described online ahead of print in Clinical Cancer Research.
Sanja Dacic, MD, PhD, Appointed Vice Chair and Director of Anatomic Pathology at Yale Pathology
Sanja Dacic, MD, PhD, an internationally renowned and highly accomplished leader in anatomic pathology, has been appointed Vice Chair and Director of Anatomic Pathology in the Department of Pathology at Yale School of Medicine, effective May 1, 2022.
Yale Test of Immunotherapy Drug for Advanced Lung Cancer Shows Promise
Researchers at Yale Cancer Center have found that use of the checkpoint inhibitor pembrolizumab in place of radiation can extend life with very few side effects in patients with advanced metastatic lung cancer.Source: YaleNews
Study: Drug Has Long-term Survival Benefit for Some Lung Cancer Patients
“The response that we have seen from pembrolizumab, in a subset of patients years after treatment ended, is remarkable, especially since their chemotherapy had initially failed,” said Roy S. Herbst, M.D., Ph.D., chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital and director for translational research at Yale Cancer Center.
Using the Immune System to Target Cancer
A former Navy pilot, Ray leads an active life and was anxious to return to his usual level of activity. He was totally blindsided when he received a diagnosis of lung cancer, and further devastated by the news that it had spread to his pancreas and possibly his brain. He learned he was eligible for a clinical trial to test pembrolizumab, a drug helps the immune system fight cancer by blocking a pathway that prevents immune cells from destroying cancer cells.
A CT college prof’s eye exam led to a cancer diagnosis. Here’s why she said there’s ‘karma in this’
“Here I am going in for a routine eye exam and now all of a sudden I have a possible malignant spot on my lung. I mean talk about shell shock,” she said. Before the time came for the MRI on that Thursday — which didn’t detect anything suspicious — Vanderlick was already speaking with Dr. Sanket Thakore, a pulmonary specialist who treats and diagnoses critical lung conditions with minimally invasive techniques. Thakore immediately discussed taking a biopsy since Vanderlick was already in the hospital, she said. “When you have something suspicious like that you want to know right away about how bad it is,” Vanderlick said. “With this alone, you are already overwhelmed and don’t want a lot of drama or trauma even more than you are already experiencing.” On Friday that same week, Thakore used a new technique called robotic bronchoscopy procedure, and available at YNHH.Source: The Hartford Courant